Targeted breast cancer treatment approved for routine NHS use

Women with advanced breast cancer could soon have access to a new targeted treatment on the NHS, following a decision by the National Institute for Health and Care Excellence (NICE). The tablet capivasertib, used alongside fulvestrant, has been approved for patients with hormone receptor-positive, HER2-negative breast cancer that has progressed after earlier endocrine treatment. It […]

Read More  on the NHS website.